Breast cancer (Tokyo, Japan)最新文献

{"title":"Five-year outcomes of partial breast proton beam therapy without lumpectomy for early-stage breast cancer: an interventional prospective study.","authors":"Etsuyo Ogo, Takeshi Arimura, Takashi Ogino, Uhi Toh, Kenta Murotani, Ichiro Isomoto, Makoto Kubo, Reiki Nishimura, Yusaku Miyata, Gen Suzuki, Yoshio Hishikawa, Shoshu Mitsuyama, Ryoichi Nagata","doi":"10.1007/s12282-026-01916-6","DOIUrl":"https://doi.org/10.1007/s12282-026-01916-6","url":null,"abstract":"<p><strong>Background: </strong>We report on our initial clinical experience with partial breast proton beam therapy (PB-PBT) without tumor resection as an alternative to partial mastectomy for low-risk early-stage breast cancer.</p><p><strong>Methods: </strong>This trial commenced in 2015, and eligibility criteria included women with cT1N0M0 invasive ductal carcinoma, estrogen receptor positivity, human epidermal growth factor receptor type-2 negativity, age of 40-70 years, and a performance status of 0 or 1. In Phase I, PB-PBT was administered at 62.4 Gy (RBE) in 26 fractions using the field-in-field technique. After confirming that no serious adverse events occurred, Phase II was conducted using the same dose. Follow-up evaluations were conducted every 3 months for the first year after irradiation and every 6 months thereafter.</p><p><strong>Results: </strong>As of December 2025, 11 patients had completed a follow-up of ≥ 5 years. The median follow-up time was 82 months. Tumors exhibited immediate shrinkage post-PB-PBT, with morphological changes on ultrasonography and magnetic resonance imaging observed within 3-6 months. No recurrence was observed within the irradiated field in patients with > 5 years of follow-up. Dermatitis was Grade 1 in 55% of cases and Grade 2 in 45%; there were no cases of Grade ≥ 3. Grade 1 telangiectasia was observed in 36% of patients after 2 years, although most patients tolerated the treatment well.</p><p><strong>Conclusion: </strong>Preliminary clinical observations suggest that PB-PBT without lumpectomy achieves results within specific criteria and that it could be an option for breast cancer treatment using radiation therapy alone.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149009646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathologic complete response and survival according to germline BRCA1/2 status in triple-negative breast cancer.","authors":"Paulina Gebhart, Florian Heinzl, Chiara Kahl, Alev Bari, Georg Langs, Daniela Muhr, Christian F Singer, Yen Y Tan","doi":"10.1007/s12282-026-01914-8","DOIUrl":"https://doi.org/10.1007/s12282-026-01914-8","url":null,"abstract":"<p><strong>Background: </strong>Germline BRCA1/2 pathogenic variants (gBRCA-PV) are associated with chemosensitivity in triple-negative breast cancer (TNBC), but whether higher pathologic complete response (pCR) rates translate into improved long-term outcomes remains uncertain. We assessed associations of gBRCA-PV status with pCR, recurrence-free survival (RFS) and breast cancer-specific survival (BCSS) in a real-world TNBC cohort treated with neoadjuvant chemotherapy (NACT).</p><p><strong>Methods: </strong>We retrospectively analyzed 293 patients with stage I-III TNBC diagnosed between 2007 and 2023 who were treated with NACT and underwent germline BRCA1/2 testing at a single tertiary center. Multivariable logistic and Cox regression models assessed pCR, RFS and BCSS.</p><p><strong>Results: </strong>Of 293 patients, 56 (19.1%) carried gBRCA-PV. The overall pCR rate was 49.5% and was higher in carriers than noncarriers (73.2% vs. 43.9%, p<0.001). After adjustment for age at diagnosis, clinical stage, NACT regimen, noncarriers had lower odds of pCR (OR 0.36, 95% CI 0.18-0.70, p=0.004). In Cox models, associations between gBRCA-PV status and RFS or BCSS did not reach statistical significance, either with or without adjustment for pCR, and estimates were imprecise. pCR was strongly associated with improved RFS (HR 0.24) and BCSS (HR 0.20) (both p<0.001).</p><p><strong>Conclusions: </strong>gBRCA-PV carriers were more likely to achieve pCR after NACT, whereas associations with RFS or BCSS remained uncertain. The limited number of events and wide confidence intervals preclude firm conclusions regarding survival differences. Larger cohorts with longer follow-up are needed to clarify the relationship between gBRCA status, treatment response and long-term outcomes.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148932448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Initial activities and prospects of MIRAY1: a youth-driven, society-endorsed initiative to cultivate future breast cancer physicians.","authors":"Hiroko Masuda, Takaaki Konishi, Mai Onishi, Aki Ito, Kazunoshin Tachibana, Akari Murakami, Atsushi Fushimi, Ryota Otsubo, Haruru Kotani, Yuri Kimura, Yuka Inoue, Yukinori Ozaki, Kaori Tane, Tsutomu Iwasa, Yuko Takahashi, Yuko Kanemoto, Yurika Iida, Chiaki Kudo, Sayuka Nakayama, Takahiro Suzuki, Midori Morita, Riko Sato, Masafumi Iida, Akihiko Ozaki, Mai Kitazawa, Mio Adachi, Masafumi Inokuchi, Chikako Yamauchi, Takanori Ishida, Norikazu Masuda, Masakazu Toi","doi":"10.1007/s12282-026-01906-8","DOIUrl":"https://doi.org/10.1007/s12282-026-01906-8","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148901455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exercise prehabilitation in breast cancer surgery: are we measuring the right outcomes?","authors":"Kadri Altundag","doi":"10.1007/s12282-026-01912-w","DOIUrl":"https://doi.org/10.1007/s12282-026-01912-w","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148890175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between preoperative body composition and health-related quality of life in breast cancer patients: a prospective Eastern European study.","authors":"Katarzyna Mielniczek, Radosław Mlak, Aleksandra Kowalska, Katarzyna Jóźwik, Karol Rawicz-Pruszyński, Zuzanna Pelc","doi":"10.1007/s12282-026-01911-x","DOIUrl":"https://doi.org/10.1007/s12282-026-01911-x","url":null,"abstract":"<p><strong>Purpose: </strong>The rising proportion of patients diagnosed with early-stage breast cancer (BC) has shifted the focus of oncological care toward patient-reported outcomes (PROs) as an important component of treatment evaluation. Nevertheless, data on the association between body composition and BC-specific PROs remain scarce and mainly retrospective. This study aimed to evaluate the association between preoperative bioelectrical impedance analysis (BIA) parameters and BC-specific PROs measured using the EORTC QLQ-BR23.</p><p><strong>Methods: </strong>This prospective study included 81 patients with histologically confirmed BC qualified for surgical treatment. Body composition was assessed preoperatively using multi-frequency BIA. BC-specific PROs was evaluated using the EORTC QLQ-BR23 questionnaires. Statistical analysis included the Mann-Whitney U test and Kruskal-Wallis ANOVA for group comparisons and Spearman's rank correlation coefficient to assess associations between variables.</p><p><strong>Results: </strong>Significant associations were observed between selected BIA parameters and PROs in BC patients. Higher phase angle and reactance values were positively correlated with body image, whereas higher lower-limb fat-free mass percentage and elevated TBW/FFM ratios were associated with poorer sexual functioning and enjoyment. In addition, body composition parameters differed across molecular subtypes with HER2-positive patients demonstrating lower values of total body water, fat-free mass, skeletal muscle mass and basal metabolic rate.</p><p><strong>Conclusion: </strong>These findings support the clinical utility of BIA as a complementary tool for personalized assessment linking physiological status with tumor characteristics and PROs.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148890106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Prognostic model based on six PD‑1 expression and immune infiltration‑associated genes predicts survival in breast cancer.","authors":"Shen Junjun, Zhuang Jing, Pu Jie, Chu Jian, Pan Yuefen, Han Shuwen","doi":"10.1007/s12282-026-01909-5","DOIUrl":"https://doi.org/10.1007/s12282-026-01909-5","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148890178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor-positive, HER2-negative metastatic breast cancer.","authors":"Yosuke Aoyama, Yukinori Ozaki, Masahiro Kuno, Rika Kizawa, Jun Masuda, Meiko Nishimura, Mami Kurata, Lina Inagaki, Mari Hosonaga, Ippei Fukada, Tetsuyo Maeda, Kazuyo Yoshida, Nami Yamashita, Takayuki Kobayashi, Toshimi Takano, Takayuki Ueno","doi":"10.1007/s12282-026-01908-6","DOIUrl":"https://doi.org/10.1007/s12282-026-01908-6","url":null,"abstract":"<p><strong>Background: </strong>Optimal sequencing of antibody-drug conjugates (ADCs) is an important clinical issue in metastatic breast cancer. However, data on datopotamab deruxtecan (Dato-DXd) following trastuzumab deruxtecan (T-DXd) have not been reported. This study evaluated real-world outcomes of Dato-DXd in patients with hormone receptor-positive, HER2-negative metastatic breast cancer, focusing on prior T-DXd exposure.</p><p><strong>Methods: </strong>This single-center retrospective study included patients who received at least one dose of Dato-DXd by December 2025. Outcomes were evaluated overall and by prior T-DXd exposure. Endpoints included disease control rate (DCR), objective response rate (ORR), time to treatment failure (TTF), and progression-free survival (PFS). Among patients who received prior T-DXd, TTF with T-DXd and subsequent Dato-DXd was compared.</p><p><strong>Results: </strong>A total of 45 patients were analyzed: 19 had prior T-DXd exposure and 26 were T-DXd-naïve. The cohort was heavily pretreated with a median of six prior treatment lines and three prior chemotherapy regimens for metastatic disease. Overall, the DCR and ORR were 57.8% and 24.4%, respectively; the corresponding rates were 52.6% and 10.5% in the prior T-DXd group and 61.5% and 34.6% in the T-DXd-naïve group. The median TTF and PFS were 4.2 and 4.1 months in the overall cohort, and 3.4 and 3.0 months in the prior T-DXd group, respectively. Among 16 patients evaluable for TTF with both agents, five (31.3%) had a longer TTF with Dato-DXd than with prior T-DXd.</p><p><strong>Conclusions: </strong>Dato-DXd showed limited but clinically relevant activity, including after prior T-DXd. Further studies are needed to optimize ADC sequencing.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148883402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodological considerations in prognostic modeling for HER2-positive breast cancer with lung metastasis.","authors":"Ozden Altundag, Kadri Altundag","doi":"10.1007/s12282-026-01885-w","DOIUrl":"10.1007/s12282-026-01885-w","url":null,"abstract":"","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1237-1238"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148261307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abemaciclib plus endocrine therapy in chemotherapy-treated patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.","authors":"Kazutaka Narui, Kana Miyahara, Yukari Uemura, Akimitsu Yamada, Kazuhiro Araki, Fumie Fujisawa, Takahiro Nakayama, Takashi Ishikawa, Hirohito Seki, Kimito Yamada, Masahiro Kitada, Takayuki Iwamoto, Naruto Taira, Yuichiro Kikawa, Tomohiko Aihara, Hirofumi Mukai","doi":"10.1007/s12282-026-01889-6","DOIUrl":"10.1007/s12282-026-01889-6","url":null,"abstract":"<p><strong>Background: </strong>Cyclin-dependent kinase (CDK) 4/6 inhibitors with endocrine therapy are the standard first- and second-line treatments for hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). In clinical practice, however, CDK4/6 inhibitors are also used in patients previously treated with chemotherapy, but their efficacy and safety in this setting remain unclear.</p><p><strong>Patients and methods: </strong>We conducted a multi-institutional prospective cohort study to obtain real-world evidence regarding the clinical efficacy and safety of combination therapy with abemaciclib and endocrine therapy in chemotherapy-treated patients with HR+/HER2- MBC.</p><p><strong>Results: </strong>Between December 2019 and November 2022, 181 patients were registered. The median progression-free survival (PFS) and overall survival periods for abemaciclib were 10.3 months and 25.2 months, respectively. The median number of endocrine therapies for MBC was one regimen. The median PFS period of the patients treated with abemaciclib as maintenance therapy after chemotherapy was 13.8 months. The median PFS period of patients with prior treatment history with CDK4/6 inhibitor (palbociclib) was 6.6 months. Patients with one or two chemotherapy regimens in the previous line had a significantly longer PFS period than those with three or more regimens. Regarding safety, severe adverse events were observed; these were consistent with known abemaciclib profile.</p><p><strong>Conclusion: </strong>Abemaciclib with endocrine therapy demonstrates considerable efficacy and manageable safety in chemotherapy-treated HR+/HER2-MBC. Notably, the > 1-year PFS observed when used as maintenance therapy, in the absence of disease progression, underscores its potential clinical utility.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1138-1146"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148393189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low protein, high risk: hypoalbuminemia predicts adverse outcomes after mastectomy in 37,848 breast cancer patients.","authors":"Thomas Schaschinger, Tobias Niederegger, Fortunay Diatta, Dany Y Matar, Jilian Dean, Doha Obed, Henriette Grundig, Barbara Kern, Christoph Tausch, Solange Bayard, Giacomo Montagna, Dennis P Orgill, Adriana C Panayi, Gabriel Hundeshagen, Samuel A Knoedler","doi":"10.1007/s12282-026-01875-y","DOIUrl":"10.1007/s12282-026-01875-y","url":null,"abstract":"<p><strong>Background: </strong>Hypoalbuminemia is a well-known marker of poor nutritional status and has been linked to adverse outcomes in various surgical specialties. However, its role in mastectomy remains underexplored. This study investigates the impact of hypoalbuminemia on 30-day postoperative outcomes in patients undergoing mastectomy for breast cancer.</p><p><strong>Methods: </strong>Using data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database from 2011 to 2021, we identified 37,848 female breast cancer patients who underwent mastectomy without concurrent reconstructive procedures and had documented preoperative serum albumin levels measured within 30 days of surgery. Patients were stratified by albumin level (< 3.5 g/dL vs. ≥3.5 g/dL). Multivariate logistic regression was used to assess the association between hypoalbuminemia and postoperative 30-day outcomes. ROC analysis identified albumin thresholds predictive of complications.</p><p><strong>Results: </strong>Among 37,848 patients, 3,210 (8.5%) were hypoalbuminemic. Hypoalbuminemia was significantly associated with higher rates of any complication (16% vs. 10%; OR 1.4, p < 0.001), surgical complications (10% vs. 5.5%; OR 1.5, p < 0.001), medical complications (0.37% vs. 0.13%; OR 1.8, p < 0.001). Similarly, readmissions were significantly more frequent in hypoalbuminemic patients (7.0% vs. 3.9%; OR 1.6, p < 0.001). The need for transfusion was over three times higher (5.0% vs. 1.4%, p < 0.001), and hypoalbuminemia was associated with longer hospital stays (2.2 vs. 1.3 days, p < 0.001). Subgroup analysis revealed that these trends persisted across both total and radical mastectomy procedures. Optimal albumin thresholds for predicting complications ranged from 3.7 to 4.1 g/dL, depending on the type of complication.</p><p><strong>Conclusion: </strong>Preoperative hypoalbuminemia is an independent predictor of increased postoperative morbidity following mastectomy. Clinicians may consider selective albumin assessment as a pragmatic tool for identifying patients with increased physiological vulnerability who may benefit from targeted preoperative optimization strategies, rather than as a stand-alone indicator of nutritional deficiency; however, further research is needed to establish optimal testing strategies and confirm clinical benefits.</p>","PeriodicalId":520574,"journal":{"name":"Breast cancer (Tokyo, Japan)","volume":" ","pages":"1021-1035"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148240896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}